http://www.nzherald....jectid=11731374
"
MitoQ is currently the subject of a collaborative study with Callaghan Innovation and
the University of Auckland, which assesses its effects on blood sugar and cardiovascular
health in 20 New Zealand patients.
Meanwhile, in the US, University of Colorado researchers are investigating whether it
improves physiological function in middle-aged and older adults, and a University of
Delaware team is examining its effects on
patients with moderate to severe chronic kidney disease.
"